Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Arrowhead (ARWR) to $52 from $55 but keeps an Overweight rating on the shares after its Q1 earnings this evening. The analyst is removing the value of Janssen’s (JNJ) JNJ-3989/ARO-HBV royalties from the firm’s model, which reduces its projected enterprise value to $5.57B from $5.83B.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNJ:
- Addex Therapeutics completes enrollment in part one of ADX71149 trial
- Novavax refuses to refund $700M for COVID shots never delivered, NY Times says
- J&J bankruptcy ruling an ‘incremental negative’ for 3M, says BofA
- Johnson & Johnson Stock (NYSE:JNJ): Time Heals All Wounds
- Wells sees J&J talc settlement reaching a ‘manageable’ $10B
